Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Alector logo — We are on a mission to make brain disorders history.

Alector

We are on a mission to make brain disorders history.

Founded 2013 United States South San Francisco, United States 141 employees IPO Total: $495.50M Biotechnology, Health Care +2

General Information

Company Name Alector
Founded Year 2013
Location United States South San Francisco, United States
Employees 141
Industries Biotechnology, Health Care, Health and Wellness +1
Funding Stage IPO
Business Model B2B, B2B2C, White Label
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Alector. To contact Alector, visit alector.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Alector compare?

A PDF of Alector and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Alector soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Alector

Alector, founded in 2013 and headquartered in the United States, is a cutting-edge player in the Biotechnology sector, focused on transforming approaches to Health Care and Pharmaceuticals. With the bold mission "to make brain disorders history," Alector is anchored in a late-stage clinical phase with a strong portfolio targeting neurodegenerative diseases.

The company's pioneering work addresses critical unmet needs in effectively delaying or ceasing neurodegenerative progression. Their innovative approach leverages proprietary technologies including the Alector Brain Carrier (ABC) to facilitate blood-brain barrier transport, a key challenge in treating brain disorders.

Alector's recent financial activity includes a $50.00M Post IPO Debt investment from Hercules Capital as of 01 November 2024. This bolstering of capital reflects confidence in their scientific advancements and commercial potential.

Business keywords: Neurodegenerative Diseases, Clinical Development, Antibody Discovery, Protein Engineering, Blood-Brain Barrier Technology, Alzheimer's Disease, Neuroimmunology, Genetic Targeting, Therapeutic Development, Neuroscience, Innovative Therapies, Drug Development, Lysosomal Dysfunction, Immune System Restoration

Services & Products

Development of therapies for neurodegenerative diseases
Conducting clinical trials
Research in human genetics, neuroscience, and immunology

Target Customers

Patients with neurodegenerative diseases Healthcare providers Research institutions

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Debt $50.00M 1
Hercules Capital
Hercules Capital
01 Nov 2024
Post-IPO Equity $75.00M -
01 Jan 2024
IPO $176.00M 1
AbbVie Ventures
AbbVie Ventures
01 Feb 2019
Series E $133.00M 15
Amgen Ventures Casdin Capital GV
Amgen Ventures, Casdin Capital +13
01 Jul 2018
Series D $29.50M 4
Polaris Partners SV Health Investors OrbiMed
Polaris Partners, SV Health Investors +2
01 Jan 2016
Series C $32.00M 4
Polaris Partners Mission Bay Capital OrbiMed
Polaris Partners, Mission Bay Capital +2
01 Sep 2015
Early VC Undisclosed -
01 Mar 2014
Series A Undisclosed 2
Polaris Partners OrbiMed
Polaris Partners, OrbiMed
01 Oct 2013

Alector Alternatives & Competitors

View All Alternatives
Alector vs
Cantabio Pharmaceuticals, Inc.
Cantabio Pharmaceuticals, Inc. United States

Cantabio aim to slow, stop and even prevent the onset & progression of neurodegenerative diseases.

Grant
13 employees
Biotechnology, Pharmaceutical
Alector vs
Vigil Neuroscience
Vigil Neuroscience United States

Harnessing the power of microglia to transform treatments for neurodegenerative diseases

Acquired
76 employees
Biotechnology, Health Care
Compare Alector vs Vigil Neuroscience
Alector vs
MindImmune Therapeutics, Inc.
MindImmune Therapeutics, Inc. United States

MindImmune is a pre-clinical stage company focused on neuro-inflammation, targeting Alzheimer's dise...

Series A
12 employees
Biotechnology, Pharmaceutical
Also compare with: Alector vs Lys Therapeutics Lys Therapeutics Alector vs AFFiRiS AG AFFiRiS AG View all alternatives

FAQ About Alector

We are on a mission to make brain disorders history.
Alector was founded in 2013.
Alector is headquartered in South San Francisco, United States.
Alector operates in Biotechnology, Health Care, Health and Wellness and Pharmaceutical. Its work centres on Neurodegenerative Diseases, Clinical Development, Antibody Discovery and Protein Engineering. Its customers include Patients with neurodegenerative diseases, Healthcare providers and Research institutions.
Alector has a B2B, B2B2C and White Label business model. Its revenue comes from Product Sales, Licensing and Performance Based.
Alector has approximately 141 employees.
Alector has completed 8 funding rounds, raising a total of $495.50M. The latest funding stage is IPO.
Alector offers: Development of therapies for neurodegenerative diseases, Conducting clinical trials, Research in human genetics, neuroscience, and immunology.
Top alternatives and competitors to Alector include Cantabio Pharmaceuticals, Inc., Vigil Neuroscience, MindImmune Therapeutics, Inc., Lys Therapeutics, AFFiRiS AG. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Alector and Cantabio Pharmaceuticals, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Alector, https://bouncewatch.com/company/alector, updated 16 June 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes